Abstract
British Journal of DermatologyVolume 184, Issue 2 p. e42-e42 Plain Language SummaryFree Access The global burden of disease of atopic dermatitis from 1990–2017 First published: 05 February 2021 https://doi.org/10.1111/bjd.19733AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Atopic dermatitis (AD; also called atopic eczema) is a common skin disease which can cause a lot of burden. The Global Burden of Disease (GBD) Study provides information on burden of diseases world-wide, including AD. The aim of this study, conducted by a team of researchers and patients from the U.S.A., the U.K. and the Netherlands, was to analyse and report the information on AD from the GBD Study between 1990 and 2017. The GBD Study does not report on individual burden of disease, but on the total burden of disease per country/region, using a measure called DALY-rate (disability adjusted life years). In their 2017 list of the burden of diseases, AD ranked number 15 (1 is highest burden) among all non-fatal diseases. Among skin diseases, AD ranked number 1. Between 1990 and 2017 we found no increase in the burden of AD. But the burden does vary a lot per country and geographical region. We do not know why, but lifestyle factors and wealthiness are probably contributing factors. In 2017, the three countries with the highest disease burden were Sweden, the United Kingdom and Iceland. The lowest three were Uzbekistan, Armenia and Tajikistan. To illustrate the difference: Sweden had a DALY-rate of 326.91 and Tajikistan 85.11. The total number of people world-wide who had AD in 2017 was almost the same as in 1990. We observed a peak in people with AD during early childhood, and this decreased steadily in young adults. But from middle-age onwards, the number of people with AD increased again. The GDP Study confirmed the high burden of disease of AD, but reported no significant change since 1990. It also showed great variety of the burden and the numbers of people with AD per country, geographical region and age-group. The reasons for this variety are not yet fully understood. Linked Article: Laughter et al. Br J Dermatol 2021; 184:304–309. Volume184, Issue2February 2021Pages e42-e42 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
